Clinical trial
A Trial of Heparin in Patients With Severe Sepsis Who Are Undergoing Treatment…
NCT00049777 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00049777 |
|---|---|
| Title | A Trial of Heparin in Patients With Severe Sepsis Who Are Undergoing Treatment With Drotrecogin Alfa (Activated) |
| Official title | A Randomized, Double-Blind, Placebo-Controlled Trial of Prophylactic Heparin in Patients With Severe Sepsis and Higher Disease Severity Who Are Undergoing Treatment With Drotrecogin Alfa (Activated) |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Sepsis |
| Intervention type | Drug |
| Interventions | Drotrecogin Alfa (Activated), Unfractionated heparin, Low molecular weight heparin |
| Enrollment | 2,000 |
| Start date | Dec 1, 2002 |
| Completion | Aug 1, 2005 |
| First posted | Nov 15, 2002 |
| Last update posted | Jan 26, 2007 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: